Biomarin Pharmaceutical Inc.
BiotechBiomarin Pharmaceutical Inc. is a biotechnology company with 1 FDA-approved products.
Biomarin Pharmaceutical Inc. at a Glance
- Growing R&D activity with 9 trials in last 2 years
Biomarin Pharmaceutical Inc.'s Key Drugs
Biomarin Pharmaceutical Inc.'s core commercial portfolio centers on Roctavian — its most strategically important drugs approved in the last 15 years.
Biomarin Pharmaceutical Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Biomarin Pharmaceutical Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Biomarin Pharmaceutical Inc.'s Therapeutic Areas
Disease areas where Biomarin Pharmaceutical Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Biomarin Pharmaceutical Inc. Pipeline Snapshot
Active clinical trials for Biomarin Pharmaceutical Inc. across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Roctavian leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 13/20 completed
- • Speed: 44 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-06-28
- Latest
- 2023-06-28
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges